The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Treatment challenges in myelofibrosis
Treating myelofibrosis is accompanied by several complications that must be considered, including thrombocytopenia and anemia. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital, London, UK, speaks about how to address these challenges in myelofibrosis and other myeloproliferative neoplasms. She discusses how activin receptor antagonists like luspatercept can release the block on the terminal phases of erythropoiesis for anemia management, and how thrombocytopenia can be treated using combination therapies. Finally, she discusses how to identify disease progression in patients treated with JAK inhibitors, and how to combat this progression, again mentioning combination therapies.
